A multicenter Phase II trial enrolled patients with platinum-sensitive recurrent ovarian cancer and randomized them to receive either the combination of the PARP inhibitor olaparib with paclitaxel and carboplatin or chemotherapy alone. Here, PARP1 is linked to ovarian carcinoma.